Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Lilly's new series of muscarinic cholinergic receptor agonists

May 24, 1996

Biogen introduces Avonex in first market

May 24, 1996

ICN will market fluoxetine in Russia, ex-Yugoslavia

May 24, 1996

Fujisawa, Nihon Shokubai claim CCK-B antagonists

May 24, 1996

ADIR claims melatonin receptor ligands for CNS disorders

May 24, 1996

Ultiva okayed for marketing in Germany; U.S. approval recommended by committee

May 24, 1996

Rizatriptan NDA filing expected in mid-1997

May 24, 1996

L-742694: Morpholine-based NK1 antagonist

May 24, 1996

CP-122721 shows potent affinity for NK1 receptors after oral dosing

May 24, 1996

Myotrophin up for advisory committee review

May 17, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
Deep brain stimulation from the shallows: tomorrow’s BCI technology?
BioWorld
Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...